Reference

Compare peptides

Two to four compounds, field by field: identity, United States regulatory status, and what kinds of documents are on file. The table records differences. It does not rank them.

Compound 1

Compound 2

Compound 3 (optional)

Compound 4 (optional)

No winner, no score, no recommendation. Counts describe how many documents of each kind Therapept has indexed — not how well a compound works, and not how much has been published overall.

Link to this comparison: /compare?peptides=pyrilutamide,finasteride,dutasteride

Side-by-side comparison of Pyrilutamide, Finasteride, Dutasteride
Identity
	Pyrilutamide	Finasteride	Dutasteride
Class	Investigational topical nonsteroidal androgen-receptor antagonist	Small-molecule 5-alpha-reductase type II inhibitor, supplied as oral tablets	Small-molecule inhibitor of both type I and type II 5-alpha-reductase, supplied as oral capsules
Also listed as	KX-826, KX826, Pyrilutamide topical	Propecia, Proscar, MK-906	Avodart, GI-198745, GG-745
Molecular formula	Not recorded	C23H36N2O2	C27H30F6N2O2
Molecular weight	Not recorded	372.55 g/mol	528.53 g/mol
CAS	Not recorded	98319-26-7	164656-23-9
PubChem CID	Not recorded	57363	6918296
Sequence length	Not recorded	Not recorded	Not recorded
Data caveat	None recorded	None recorded	None recorded
United States regulatory status
Status	Investigational	FDA-approved drug substance	FDA-approved drug substance
FDA application	None recorded	NDA 020788 (PROPECIA) — approved 19 December 1997	None recorded
Compounding	No FDA compounding entry recorded	No FDA compounding entry recorded	No FDA compounding entry recorded
WADA	Not named in this record	Not named in this record	Not named in this record
Research profile
Research purpose	Topical androgen-receptor blockade	Approved oral androgen-pathway treatment	Dual 5-alpha-reductase inhibition
Proposed mechanism	A nonsteroidal androgen-receptor antagonist applied to the scalp, intended to reduce androgen signalling in follicle cells. The clinical advantage over existing treatments is not established.	Inhibits type II 5-alpha-reductase, reducing conversion of testosterone to dihydrotestosterone. Lower scalp DHT slows follicular miniaturisation in responders.	Inhibits type I and type II 5-alpha-reductase, reducing DHT. The longer half-life means effects and adverse events persist longer after stopping than with finasteride.
Human evidence	Phase 2 trials in men and women and a Phase 3 trial in Chinese men are registered; the Phase 2 studies are listed as completed. No approved product.	Randomised trials in men with mild-to-moderate androgenetic alopecia support the approved indication. It is not approved for women.	Trials and reviews support off-label use in male androgenetic alopecia; Japan and South Korea have approved it for that indication. It is not FDA-approved for hair loss.
Evidence tier	Phase 3 trials registered or reported	Approved drug product in the United States	Approved drug product in the United States
Known safety concerns	Topical androgen-receptor blockade may still produce systemic effects; the trials are designed to measure this. Phase 3 safety data are not available here as a peer-reviewed report. Long-term safety is unknown.	The label carries warnings and precautions, including sexual adverse experiences and effects on prostate-specific antigen. Finasteride is not indicated for women; the label addresses pregnancy risk. This record is not a complete safety profile or a prescribing guide.	The approved label carries warnings and precautions, including sexual adverse experiences and prostate-cancer considerations. The long half-life means adverse effects may persist after discontinuation. Off-label status means the hair-loss risk-benefit discussion is not covered by an approved label.
Evidence gaps	Peer-reviewed Phase 3 efficacy and safety results. Whether topical delivery avoids meaningful systemic androgen blockade. Durability and any regulatory decision.	Reliable prediction of who will respond. The natural history of reported persistent sexual adverse effects after stopping. Long-term outcomes beyond the trial periods.	Long-term hair outcomes in a United States regulatory context. The clinical significance of the greater DHT suppression. Persistent adverse effects after discontinuation.
Head-to-head evidence	No published head-to-head trial against finasteride or minoxidil.	Dutasteride and finasteride have been compared in trials and reviews, but dutasteride is not FDA-approved for hair loss in the United States.	Comparative trials and reviews exist, but they do not establish that dutasteride's greater DHT suppression produces a proportionally greater clinical benefit.
Named pathways	Androgen receptor · DHT signalling · Follicular miniaturisation	5-alpha-reductase type II · DHT synthesis · Androgen receptor signalling	5-alpha-reductase type I · 5-alpha-reductase type II · DHT synthesis
Evidence on file
Records	2Open evidence file	1Open evidence file	1Open evidence file
Human-interventional records	2	0	0
Human-observational records	0	0	0
Animal records	0	0	0
In-vitro records	0	0	0
Reviews	0	0	1
Regulatory documents	0	1	0
Earliest indexed	2022	2022	2022
Latest indexed	2024	2022	2022

Every identity and regulatory value above is taken from the compound’s record, where its sources are listed. Evidence counts are derived from the published evidence file at build time. A missing class means no document of that kind is indexed — not that none exists.

Overlapping pathways

Named in the mechanism discussion for at least two of these compounds: 5-alpha-reductase type II · DHT synthesis.

Shared biology is not shared evidence. No claim of synergy is made here, and overlapping pathways do not mean the compounds have been studied together.